Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 6/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6675119 | 0.88 | MIF (0.31) | MIFTSHR | |
| SCHEMBL3246192 | 0.84 | MIF (0.37) | MIFESR1ESR2 | |
| SCHEMBL6889221 | 0.82 | MIF (0.39) | MIFMAPK1ALDH1A1TAAR1ALOX15 | |
| SCHEMBL2241061 | 0.82 | MIF (0.39) | MIFMAPK1ALDH1A1TAAR1ALOX15 | |
| SCHEMBL331446 | 0.79 | MIF (0.36) | MIFALDH1A1CYP3A4TRPA1HPGD | |
| SCHEMBL109897 | 0.77 | MAPK1 (0.39) | MAPK1ALDH1A1TAAR1ALOX15ESR1 | |
| SCHEMBL1980336 | 0.77 | MIF (0.35) | MIFMAPK1ALDH1A1TAAR1ALOX15 | |
| SCHEMBL8763980 | 0.77 | MIF (0.37) | MIFMAPK1ALDH1A1ESR1CYP3A4 | |
| SCHEMBL26965552 | 0.77 | CYP19A1 (0.36) | MIFALDH1A1TAAR1CYP3A4MAPT | |
| SCHEMBL4386996 | 0.76 | MIF (0.42) | MIFMAPK1ALDH1A1CYP3A4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| EP-0349195-B1 | Direct synthesis by cationic polymerization of nitrogen-containing polymers | EXXON CHEMICAL PATENTS INC (US) | 1997-05-21 | — | — | EP | disclosed |
| US-5629394-A | ENDCAPPING ADDITION POLYMERS WITH NITROGEN FUNCTIONAL GROUPS WHICH CAN BE FURTHER DERIVATIZED | EXXON CHEMICAL PATENTS INC (US) | 1997-05-13 | — | — | US | disclosed |
| US-5444135-A | Polymerization and functionalization with nitrogen-containing functional groups occur simultaneously | EXXON CHEMICAL PATENTS INC. (US) | 1995-08-22 | — | — | US | disclosed |
| US-5336745-A | Terminally-substituted polymeric compositions from cationically polymerizable monomers and initiators | EXXON CHEMICAL PATENTS INC. (US) | 1994-08-09 | — | — | US | disclosed |
| US-5032653-A | Catalysts | EXXON CHEMICAL PATENTS, INC. (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0349195-A2 | Direct synthesis by cationic polymerization of nitrogen-containing polymers | EXXON CHEMICAL PATENTS INC. (US) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | MIF 83/4885MAPK1 60/4885ALDH1A1 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.